Publishing is paused. This is a dated archive; older articles and guides may be outdated or unreviewed. Contact Chip about a correction.
Finance

Davita’s Cendialcon Deal Puts Dialysis Payment Cycles Under the Microscope

Chip MorenoChip Moreno||Source: Primicias

Ecuador's Superintendence of Economic Competition authorized Davita's acquisition of 100% of the shares of Centro de Diálisis Contigo Cendialcon Cía. Ltda. The transaction was reviewed in the private-complementary hemodialysis markets of Latacunga and Ambato.

The regulator concluded that the purchase did not change the structure of those markets or create immediate horizontal anticompetitive risks. The same decision sits alongside a broader national expansion signal: Davita's group already has a network of 29 establishments in Ecuador.

Demand is structurally large

Around 20,000 people in Ecuador need dialysis or hemodialysis to survive. The state has covered the treatment since 2008 because it is classified as a catastrophic illness, but the public system lacks enough capacity and refers 88%, or about 17,000 patients, to private clinics.

The reported treatment cadence is three sessions of four hours per week per patient. That makes provider reliability and reimbursement timing material operating variables, not side issues.

The receivables signal

Cendialcon closed 2025 with 261 patients, up 11.5% from the previous year. Its accounts receivable reached USD 5.71 million, 27.13% above 2024, and its average collection time reached 486 days. Primicias attributes the balance primarily to pending payments from the Ministry of Public Health and IESS.

For an operator, that profile combines demand growth with working-capital pressure. For a buyer, the transaction is therefore about more than clinic count: it also brings exposure to payer concentration, public payment cycles, and the ability to finance ongoing treatment.

What to watch

The competition approval does not disclose a purchase price or a post-close operating plan. The key indicators are whether consolidation changes network capacity, how public reimbursements move through the system, and whether collection times improve.

The transaction is a healthcare-market event with financial infrastructure attached. The competitive finding is limited to the reviewed markets; the payment-cycle figures show why the sector still deserves close operating and credit attention.

Source: Primicias

Source

Primicias — “Davita compra el 100% de Cendialcon, empresa de hemodiálisis en Ecuador”

View original
dialysishealthcareDavitaCendialconreimbursement risk
Companies: Davita, Cendialcon, Ministry of Public Health, IESS
Regions: Cotopaxi, Tungurahua, Ecuador
Share
Research Support

Support the EcuadorBrief archive.

Research support helps fund review, corrections, and hosting. New publishing is paused.

Newsletter paused

EcuadorBrief is not sending daily briefings while the archive is under review.

Join Chip's personal newsletter
Opens WhatsApp with a pre-filled message